The downward movement pushed Sun Pharma's stock price down to Rs 1,762.40 during morning trade on November 5, 2026. This daily loss of 0.62 percent dropped the company below its 20-day Exponential Moving Average. At the time of the update, that specific technical indicator was positioned at Rs 1,772.93. Market participants monitoring moving averages will note this shift below the short-term threshold.
Key points
The stock has dipped below its designated 20-day Exponential Moving Average benchmark.: The stock has dipped below its designated 20-day Exponential Moving Average benchmark.
Selling pressure resulted in a morning share price decline of 0.62 percent.: Selling pressure resulted in a morning share price decline of 0.62 percent.
The current trading price sits roughly ten rupees beneath the key moving average.: The current trading price sits roughly ten rupees beneath the key moving average.
Sources checked by our analysis pipeline: 1
09:36:05 AM IST, 05 Nov 2026
Sun Pharma Share Price Live Updates: Sun Pharma crosses below its 20-day Exponential Moving Average
Sun Pharma has just crossed below its 20-day Exponential Moving Average, with a current price of Rs 1762.40, a daily change of -0.62%, and the 20-day EMA at 1772.93.
SC Agrotech Limited's leadership is convening to evaluate multiple shareholder-friendly measures that could significantly alter its capital structure and reward investors. The proposed agenda aims to enhance share liquidity and distribute profits following exceptional equity appreciation over the past year. If approved, the corporate actions will require necessary statutory endorsements and alterations to the firm's foundational charter.
Wall Street veteran Jared Dillian warns that inexperience is leaving modern market participants dangerously vulnerable to severe financial declines. Because many individuals have never navigated a major collapse, they fail to anticipate the risks of sudden downturns. To mitigate this exposure, Dillian has formulated an actionable risk-management approach to safeguard portfolios against substantial drawdowns.
Mold-Tek Technologies experienced aggressive market demand following the release of record quarterly earnings that nearly equaled its entire bottom line from the previous fiscal year. Robust operational execution and diversification into higher-value engineering domains have sharply accelerated profitability. This rapid turnaround positions the firm to capitalize on an expanding client base across its core industrial segments.